Long-term multikinase inhibitor therapy was associated with a 7.3% incidence of major adverse cardiac events among 41 treated patients, suggesting a link to accelerated coronary atherosclerosis.
Observational (n=41)
No
Does long-term multikinase inhibitor therapy increase the risk of major adverse cardiac events in cancer patients?
Long-term multikinase inhibitor therapy may increase the risk of severe ischemic cardiac events due to accelerated atherosclerosis, highlighting the need for close cardiovascular monitoring in oncology patients.
Objective: To investigate the incidence and characteristics of ischemic cardiac events, specifically major adverse cardiac events (MACE), in patients undergoing long-term treatment with multikinase inhibitors (MKIs) such as lenvatinib and sorafenib. Methods: A single-center retrospective analysis was conducted on 41 patients treated with lenvatinib or sorafenib for more than one year at our institution from 2015 to 2022. Patient records were reviewed to collect data on demographics, cancer type, cardiovascular risk factors, MKI treatment duration, and MACE incidence. MACE events, defined as acute heart failure, fatal arrhythmia, acute myocardial infarction, and coronary revascularization, were analyzed to determine potential correlations with MKI therapy. Results: Among the 41 patients, three (7.3%) developed MACE, presenting as acute heart failure, fatal arrhythmia, and acute myocardial infarction, all associated with significant coronary artery stenosis. Notably, none of these patients had a prior history of cardiovascular disease. Despite variations in clinical presentation, all cases suggested a link between long-term MKI administration and accelerated coronary atherosclerosis. Factors involved in atherosclerosis were significantly older and tended to be more hypertensive in the non-MACE group. Conclusions: Long-term MKI therapy may increase the risk of severe ischemic cardiac events, likely due to accelerated atherosclerosis. Clinicians and oncology nurses should monitor patients closely for early signs of angina, especially in an outpatient setting, to prevent acute cardiac events. Further large-scale studies are warranted to establish a clearer causal relationship between MKI therapy and cardiovascular risks.
Muraoka et al. (Tue,) conducted a observational in Cancer patients on multikinase inhibitors (n=41). Long-term multikinase inhibitors (lenvatinib and sorafenib) was evaluated on Major adverse cardiac events (MACE). Long-term multikinase inhibitor therapy was associated with a 7.3% incidence of major adverse cardiac events among 41 treated patients, suggesting a link to accelerated coronary atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: